Ranolazine is a novel anti-anginal agent with a “non-haemodynamic” mechanism of action. It is effective as adjunctive therapy in patients with chronic stable angina whose symptoms are not controlled by conventional treatment. The clinical development program of ranolazine has shown that the drug improves exercise performance, reduces angina attacks and hence the use of sublingual nitrates, compared to placebo. Ranolazine is well tolerated with neutral effect on cardiovascular haemodynamics. Besides its role in chronic stable angina, ranolazine may be useful in other cardiovascular conditions in the future. This chapter will focus on the mechanism of action of ranolazine and briefly review current evidence supporting its role as a suitable treatment for stable angina pectoris.
Ranolazine
Volterrani M
2015-01-01
Abstract
Ranolazine is a novel anti-anginal agent with a “non-haemodynamic” mechanism of action. It is effective as adjunctive therapy in patients with chronic stable angina whose symptoms are not controlled by conventional treatment. The clinical development program of ranolazine has shown that the drug improves exercise performance, reduces angina attacks and hence the use of sublingual nitrates, compared to placebo. Ranolazine is well tolerated with neutral effect on cardiovascular haemodynamics. Besides its role in chronic stable angina, ranolazine may be useful in other cardiovascular conditions in the future. This chapter will focus on the mechanism of action of ranolazine and briefly review current evidence supporting its role as a suitable treatment for stable angina pectoris.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
